Guggenheim Maintains Buy on Immunovant, Raises Price Target to $44
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $41 to $44.
Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $41 to $44.